The PER (Preoperative Esophagectomy Risk) Score: A Simple Risk Score to Predict Short-Term and Long-Term Outcome in Patients with Surgically Treated Esophageal Cancer

Matthias Reeh, MD, Johannes Metze, MD, Faik G. Uzunoglu, MD, Michael Nentwich, MD, Tarik Ghabban, MD, Ulrich Wellner, MD, Maximilian Bockhorn, MD, Stefan Kluge, MD, Jakob R. Izbicki, MD, PhD, and Yogesh K. Vashist, MD, PhD

Abstract: Esophageal resection in patients with esophageal cancer (EC) is still associated with high mortality and morbidity rates. We aimed to develop a simple preoperative risk score for the prediction of short-term and long-term outcomes for patients with EC treated by esophageal resection.

In total, 498 patients suffering from esophageal carcinoma, who underwent esophageal resection, were included in this retrospective cohort study. Three preoperative esophagectomy risk (PER) groups were defined based on preoperative functional evaluation of different organ systems by validated tools (revised cardiac risk index, model for end-stage liver disease score, and pulmonary function test). Clinicopathological parameters, morbidity, and mortality as well as disease-free survival (DFS) and overall survival (OS) were correlated to the PER score.

The PER score significantly predicted the short-term outcome of patients with EC who underwent esophageal resection. PER 2 and PER 3 patients had at least double the risk of morbidity and mortality compared to PER 1 patients. Furthermore, a higher PER score was associated with shorter DFS ($P < 0.001$) and OS ($P < 0.001$). The PER score was identified as an independent predictor of tumor recurrence (hazard ratio [HR] 2.1; $P < 0.001$) and OS (HR 2.2; $P < 0.001$).

The PER score allows preoperative objective allocation of patients with EC into different risk categories for morbidity, mortality, and long-term outcomes. Thus, multicenter studies are needed for independent validation of the PER score.

(introduction)

Cancer of the esophagus is one of the 10 most newly diagnosed cancers worldwide. Surgery is still the only curative therapy option for esophageal cancer (EC). The long-term survival is poor. The mortality and morbidity associated with esophagectomy for EC, even in high-volume centers, remain high. However, prediction of perioperative outcome is essential not only for eligible patient selection but also for treatment strategy. Predictive factors for perioperative mortality have been reported previously including sex, age, and comorbidities, as well as experience of the operating surgeon, hospital volume, and neoadjuvant therapy. Accurate preoperative risk assessment of patients with EC is the most promising way to reduce mortality and morbidity and provides a tool to compare the quality of care between different institutions. Several authors reported on risk prognostic models and the use of normograms in EC surgery. Several scores were developed based on the models for perioperative mortality, like the Bartels score and the Physiological and Operative Severity Score for the enumeration of Mortality adjusted for esophagogastro surgery (O-POSSUM). The reported risk models were restricted to predict mortality or morbidity or required special tests (e.g., the aminopyrine breath test in Bartels score). Other scores failed to predict mortality correctly, like the O-POSSUM. Indeed, no predictive model has been developed to assess the perioperative risk and long-term outcome for patients undergoing resection for EC. A standardized preoperative risk-assessment tool is still missing. Such a score should be easy to use and based on simple tests that are globally available in daily clinical work.

The aim of this study was to develop a simple risk score based on routine diagnostic work-up that is able to predict the short-term outcome (mortality and morbidity) as well as the long-term survival of patients undergoing esophageal resection for EC.
METHODS

The study was approved by the Medical Ethical Committee of Hamburg. Between 1994 and October 2007, a total of 540 patients underwent esophageal resection for EC at the Departments of General, Visceral and Thoracic Surgery of the University Medical Center Hamburg-Eppendorf, Germany. Only patients who had a complete resection (R0) and had histologically proven EC were included in the study. Informed consent was obtained from all patients before including them in a prospective database. All patients had a detailed preoperative assessment of their general health condition and organ function evaluation. Routine tumor staging included esophagogastroduodenoscopy, computed tomography, and blood tests. Operating technique was dependent upon tumor location. Until 1999 our primary approach was a transhiatal (TH) resection with a collar anastomosis, whereas from 2000 onward we primarily performed a thoracoabdominal (TA) resection with a high-intrathoracic anastomosis. Perioperative mortality was defined as 30-day posthospital discharge mortality. The perioperative morbidity included any type of medical or surgical complication appearing within the hospital stay or leading to rehospitalization within 30 days after discharge. Clinical follow-up data were obtained by studying the patients’ clinical charts and by contacting them on an outpatient basis or by phone.

The Preoperative Esophagectomy Risk Score

The main condition for the development of the preoperative esophagectomy risk (PER) score was simplicity. We focused on diagnostic parameters preoperatively available in a routine diagnostic work-up. Furthermore, we evaluated validated diagnostic tools to assess different organ systems. The composition of the PER score is depicted in Table 1. The revised cardiac risk index (RCRI), the model for end-stage liver disease (MELD) score, and the pulmonary function test (PFT) were chosen as the defining parameters of the PER score. For the RCRI, the preoperative medical history of each patient was studied and each variable (high-risk surgery, history of ischemic heart disease, history of congestive heart failure, history of cerebrovascular disease, insulin-dependent diabetes mellitus, and preoperative serum creatinine >2.0 mg/dL) was assigned a point. Each point was transferred to the PER score. The MELD score was developed to predict the mortality of patients awaiting liver transplantation but has also been correlated to outcomes in nonhepatic surgery. The MELD score is based on the following parameters: serum creatinine, bilirubin, and international normalized ratio for prothrombin time (INR) (MELD = 3.78 × ln[serum bilirubin (mg/dL)] + 11.2 × ln[INR] + 9.57 × ln[serum creatinine (mg/dL)] + 6.43). The MELD score subgrouping was based on the upper-limit values of the particular parameter (creatinine, INR, and bilirubin) predefined at our institution. A MELD score higher than 8 points was assigned 2 points. The vital capacity (VC) and the forced expiratory volume in 1 s (FEV1) were used to classify patients in to 3 different pulmonary function groups. The cutoff values to define the 3 different subgroups with good, moderate, or poor pulmonary function were based on data published in the literature. The cutting values are given in Table 1.

Assessment of the different organ systems resulted in risk points that were summed to PER score groups. If none of the organ systems was impaired the patient was assigned to the PER group 1. Moderate impairment of 1 organ system resulted in risk points of PER score 2. If 2 or more organ systems or severe impairment of 1 organ system directed patients to PER group 3 (see Table 1).

Characterization of the Study Population

Five hundred forty patients underwent esophageal resection at our institution between 1994 and 2007. Forty-two patients received resection for diseases different from EC, were lost to follow-up, or had incomplete data and were therefore excluded from this study. Complete data and follow-up were available for 498 patients. All 498 patients were surgically treated for EC and had histologically proven EC. None of the patients received neoadjuvant chemotherapy or chemoradiotherapy. The median age of the study population was 63.2 years ranging from 34.5 to 85.2 years. There were 393 (79.9%) males and 105 (21.1%) females. Table 2 depicts the tumor-specific patient characteristics of the entire study population.

### TABLE 1. Preoperative Esophagectomy Risk (PER) Score Design and Classification

| Organ System   | Tool        | Value | Points | PER Score | PER Risk Group |
|----------------|-------------|-------|--------|-----------|----------------|
| Cardiovascular | RCRI        | 0     | 0      | <4 (no impaired organ system) | 1 (low, PER score < 4) |
|                |             | 1     | 1      |           |                |
|                |             | 2     | 2      |           |                |
|                |             | >3    | 3      |           |                |
| Pulmonary      | Lung-function testing | VC > 80% or FEV1 > 80% | 1 | 2 (intermediate, PER score 4) |
|                |             | FEV1 > 60% to ≤80% or VC > 60% to ≤80% | 2 | 4 (impairment of 1 organ system) |
| Hepato-renal   | MELD score  | 6.43 ≤ | 1 | 1 | 2 (intermediate, PER score 4) |
|                |             | 8      | 2      |           |                |

FEV1 = forced expiratory volume in 1 s, MELD = model of end-stage liver disease, RCRI = Revised Cardiac Risk Index, VC = vital capacity.
Statistical Analysis

For statistical analysis, SPSS for Windows (version 20.0; IBM Corporation, Armonk, NY) was used. The chi-squared test was used to analyze correlations between clinicopathological parameters and PER score groups. To evaluate the prognostic significance of the PER score for perioperative morbidity and mortality, univariate and multivariate logistic regression analyses were performed, and an odds ratio (OR) with 95% confidence interval (95% CI) was calculated. Survival curves of the patients were plotted using the Kaplan–Meier method and analyzed using the log-rank test. Univariate and multivariate Cox regression analyses were performed to determine the hazard ratio (HR) of different variables for overall survival (OS). Significant statements refer to P values of 2-tailed tests that were <0.05.

RESULTS

The majority of the patients belonged to the low-risk group PER 1 (54.6%), 31.1% were classified in the intermediate-risk group PER 2, and 14.3% were assigned to the high-risk group PER 3. Overall, perioperative mortality accounted for 14.3% and perioperative morbidity for 34.1% of the entire study population.

Relation of the PER Score With Clinicopathological Parameters and Perioperative Outcome

Table 2 shows the results of the correlation analyses of the PER score groups to clinicopathological parameters. A highly significant correlation was found between the PER score and perioperative outcome in terms of mortality and morbidity. Almost 50% of the patients in the PER 2 and PER 3 groups developed complications in the postoperative course, and almost 18% of the patients in the PER 2 group and 27% in the PER 3 group died perioperatively (P < 0.001 each, Table 2).

In the univariate analysis, age and PER score were the only variables reaching statistical significance for perioperative mortality (data not shown). Both parameters were entered into a logistic regression model to evaluate the prognostic

### TABLE 2. Patient Characteristics and Correlation of the PER Score With Clinicopathological Parameters

| Variables          | PER 1 | PER 2 | PER 3 | Total | P*  |
|--------------------|-------|-------|-------|-------|-----|
| Sex Male           | 205 (52.2) | 132 (33.6) | 56 (14.2) | 393 (78.9) | 0.06 |
| Sex Female         | 67 (63.8)  | 23 (21.9)  | 15 (14.3)  | 105 (21.1)  |     |
| Age, y             |        |        |       |       |     |
| ≤60                | 139 (61.5) | 59 (26.1)  | 28 (12.4)  | 226 (45.1)  | 0.02 |
| >60                | 133 (48.9) | 96 (35.3)  | 43 (15.8)  | 272 (54.6)  |     |
| UICC stage         |        |        |       |       |     |
| Stage IA           | 55 (59.1)  | 27 (29.0)  | 11 (11.8)  | 93 (18.7)   |     |
| Stage IB           | 25 (62.5)  | 12 (30.0)  | 3 (7.5)    | 40 (8.0)    |     |
| Stage IIA          | 34 (55.7)  | 23 (37.7)  | 4 (6.6)    | 61 (12.2)   |     |
| Stage IIB          | 29 (56.9)  | 15 (29.4)  | 7 (13.7)   | 51 (10.2)   |     |
| Stage IIIA         | 52 (51.5)  | 27 (26.7)  | 22 (21.8)  | 101 (20.3)  |     |
| Stage IIIB         | 27 (54.0)  | 15 (30.0)  | 8 (16.0)   | 50 (10.0)   |     |
| Stage IIIC         | 48 (50.5)  | 32 (33.7)  | 15 (15.8)  | 95 (19.1)   |     |
| Stage IV           | 2 (28.6)   | 4 (57.1)   | 1 (14.3)   | 7 (1.4)     | 0.442 |
| Differentiation    |        |        |       |       |     |
| G1                 | 11 (44.0)  | 8 (32.0)   | 6 (24.0)   | 25 (5.0)    |     |
| G2                 | 145 (55.6) | 80 (30.7)  | 36 (13.8)  | 261 (52.4)  |     |
| G3                 | 116 (54.7) | 67 (31.6)  | 29 (13.7)  | 212 (42.6)  | 0.670 |
| Cell type          |        |        |       |       |     |
| Squamous           | 145 (57.3) | 70 (27.7)  | 38 (15.0)  | 253 (50.8)  |     |
| Adeno              | 127 (51.8) | 85 (34.7)  | 33 (13.5)  | 245 (49.2)  | 0.240 |
| Mortality          |        |        |       |       |     |
| Yes                | 24 (33.8)  | 28 (39.4)  | 19 (26.8)  | 71 (14.3)   | <0.001 |
| No                 | 248 (58.1) | 127 (29.7) | 52 (12.2)  | 427 (85.7)  |     |
| Morbidity          |        |        |       |       |     |
| Yes                | 60 (35.3)  | 71 (41.8)  | 39 (22.9)  | 170 (34.1)  |     |
| No                 | 212 (64.6) | 84 (25.6)  | 32 (9.8)   | 328 (65.9)  | <0.001 |
| Operation technique|        |        |       |       |     |
| Thoraco-abdominal  | 141 (57.1) | 74 (30.0)  | 32 (13.0)  | 247 (49.6)  | 0.511 |
| Transhiatal        | 131 (52.2) | 81 (32.3)  | 39 (15.5)  | 251 (50.4)  |     |
| Tumor recurrence   |        |        |       |       |     |
| Yes                | 127 (56.4) | 69 (30.7)  | 29 (12.9)  | 225 (52.7)  | 0.710 |
| No                 | 121 (43.6) | 58 (28.3)  | 23 (11.4)  | 202 (47.3)  |     |

PER = preoperative esophagectomy risk, UICC = Union Internationale Contre le Cancer.

* Chi-squared test.
significance for perioperative mortality in patients undergoing surgical resection for EC. The PER score was found to be an independent factor for perioperative death with an OR of 2.3 in the PER 2 group and 3.8 in the PER 3 group compared to PER 1 patients (Table 3). For perioperative morbidity, PER score and operating technique were the only significant variables in the univariate analysis. The logistic regression analysis revealed a 3-times higher risk for PER 2 and almost 5-times higher risk for PER 3 of developing a complication in the postoperative course compared to PER 1 patients (Table 3). Patients undergoing TH resection, however, had an almost 50% decrement in the probability of postoperative complications in contrast to patients with TA resection. We found the increase in the PER group from 1 to 3 was paralleled by a progressive increase in the mortality and morbidity rate. The aforementioned correlation between the PER score and the presence of lymph-node metastasis as well as the prognostic significance of the PER score for perioperative mortality and morbidity remained evident also after stratification of the study population to underlying histology (adenocarcinoma [AC] vs squamous cell carcinoma [SCC]) and the type of resection performed (TA vs TH) (data not shown).

The PER Score and Oncological Outcome

The median follow-up time was 39.1 months. To verify our study group was representative of patients with EC, we calculated the OS according to the 7th edition of the Union Internationale Contre le Cancer (UICC). The OS was found to be dependent upon UICC stage and comparable to the data published by other groups (Figure 1). Patients who died peripherally were excluded from the survival analysis. The PER score did not correlate with tumor recurrence (Table 2). However, in the entire study population, a significant association between the PER score and disease-free survival (DFS) was evident (Figure 2B). This association could not be confirmed in subanalyses performed for histology and operating technique (data not shown).

In contrast, a strong correlation was found between the PER score and OS. The median OS of the study population was 21.6 months (CI: 19.1–24.2). The increase in the PER groups was paralleled by a progressive decrease in OS. The median OS in PER group 1 was the longest, with 24.8 months (CI: 18.7–30.9) compared to the shortest survival in PER group 3, with only 9.9 (CI: 1.8–17.9) months. PER 2 patients represented an intermediate group, with a survival of 19.5 months (CI: 15.8–23.2) (Figure 2A, \( P < 0.001 \)).

In our study population, 299 (60%) of the patients were found positive for regional lymph-node metastasis and 92 (18.5%) patients had distant metastases. Patients with positive lymph nodes and distant metastases in EC are known to have extremely poor survival rates, and this may be considered a bias in the correlation between the PER score and the oncological outcome. Hence, we performed survival subanalyses between the PER score and the presence or absence of lymph-node and distant metastases separately. In lymph-node negative patients without distant metastases (N0M0) the mean OS was 43.7 months (CI: 40.3–47.1, median not yet reached). A significant survival difference was evident between the different PER groups (Figure 2C). However, since the presence of lymph-node metastases correlated significantly with the PER score, only 12 patients in the N0M0 cohort belonged to the PER group 3, and the survival analysis was therefore limited to make a concise statement for PER 3 patients in this subgroup (Figure 2C). In lymph-node positive patients without distant metastases (N + M0), a similar pattern of OS to N0M0 patients

| Variables     | Morbidity OR 95% CI | P  | Mortality OR 95% CI | P  |
|---------------|---------------------|----|---------------------|----|
| Age           | 1.2 0.8–1.9         | 0.3| 1.8 1.0–3.2         | 0.05|
| Gender        | 0.8 0.5–1.3         | 0.3| 1.2 0.6–2.3         | 0.6 |
| UICC stage    | 0.9 0.8–1.2         | 0.8| 1.2 0.9–1.8         | 0.2 |
| Grading       | 1.1 0.7–1.5         | 0.8| 1.1 0.7–1.8         | 0.8 |
| Operating technique | 0.6 0.4–0.9 | 0.01| 0.5 0.3–1.0 | 0.04|
| Tumor type    | 0.8 0.5–1.2         | 0.3| 0.8 0.5–1.6         | 0.6 |
| PER score     | 2.3 1.7–3.0         | <0.001| 1.8 1.3–2.6 | 0.001|

CI = confidence interval, OR = odds ratio, PER = preoperative esophagectomy risk, UICC = Union Internationale Contre le Cancer.
was evident (Figure 2D). The median OS accounted for 18 months (CI: 15.5–20.5). An increase in PER group was paralleled by a significant stepwise decrease in OS. Patients in PER 3 displayed the poorest OS in concordance with the positive correlation to the presence of lymph-node metastases in this subcohort (Figure 2D). The median OS for PER 1 and PER 2 was 13.4 and 8.6 months, respectively, in contrast to 6.2 months for PER 3 patients ($P = 0.005$).

Since 1 may argue that the oncological outcome may be dependent upon underlying histology or the operating technique, we performed survival-stratified subanalyses in the study population according to the underlying cell type (AC and SCC) and operative procedure (TH and TA resection). In the subanalyses of patients undergoing TA and TH, PER 1 presented the longest (23.8 and 27.2 months, respectively) and PER 3 the poorest (16.6 and 9.9 months, respectively) OS ($P = 0.002$ each). In the subanalyses of patients with SCC and AC, PER 1 presented the longest (22.9 and 27.7 months, respectively) and PER 3 the poorest (9.7 and 10.4 months, respectively) OS ($P < 0.001$ and $P = 0.008$, respectively).

Univariate and multivariate analyses according to the Cox regression hazard model using age, sex, tumor size, presence of lymph-node and distant metastases, tumor differentiation, histology, operative technique, and the PER score were performed. The PER score was found to be an independent prognostic factor of survival of EC, with a HR of 1.4 (95%
CI: 1.1–1.9) for PER 2 and 2.3 (95% CI: 1.6–3.4) for PER 3 compared to PER 1 (Table 4).

The multivariate analysis was repeated after stratification of the underlying histology and operating technique was performed. However, the PER score, besides tumor size and lymph-node and distant metastases, remained throughout an independent prognostic factor of survival in EC patients. In the subanalyses, AC patients had an HR of 1.7 (CI: 1.3–2.1, \( P < 0.001 \)) and SCC patients had an HR of 1.4 (CI: 1.1–1.6, \( P = 0.005 \)) for death with increasing PER score. A similar tendency was seen in the subanalyses for operating technique. Patients undergoing TA resection had an HR of 1.7 (CI: 1.2–1.8, \( P = 0.001 \)) and patients with TH resection had an HR of 1.5 (95% CI: 1.2–1.9, \( P < 0.001 \)) for death with increasing PER score.

**DISCUSSION**

A clinically useful risk score should be easy to perform and be based on a simple diagnostic work-up. Basic diagnostic work-up for all types of major surgery includes assessment of the cardiopulmonary system and blood testing for evaluation of inflammation and hepatorenal function. Only a few of the published risk scores were able to predict mortality, and most of them failed to predict the morbidity or oncological outcome of EC patients.4,5,15–17 Furthermore, reported scores in the literature were not easy to determine due to the requirement of special tests or the need for complex algorithms. Considering the high mortality and morbidity rates associated with esophageal resection, there is an urgent need for preoperative risk stratification. Previously, Bartels et al described a risk score for the prediction of mortality with esophageal surgery.18 The Bartels score, however, requires an aminopyrine breath test to assess the hepatic function. Besides the complexity of this test, such a tool is not widely available. Furthermore, the Bartels score includes the Karnofsky index, and evaluation of the cardiac status is done without validated tools. The Karnofsky index is a widely used tool to evaluate the general condition of the patient but lacks objectivity. Importantly, the Bartels score is limited to predict only mortality. The POSSUM tool was developed to predict mortality and morbidity in patients undergoing major surgery and has been modified to O-POSSUM for utility in esophageal surgery.6,19 Apart from the extensive testing required to determine the O-POSSUM score, it failed to predict the perioperative mortality and morbidity in esophageal surgery.7

The PER score enabled risk stratification of perioperative morbidity and mortality in patients undergoing esophageal resection. The prognostic value of the PER score was not limited to mortality and morbidity but also represented an independent prognostic factor of overall oncological outcome.

The PER score reported in this study is based on validated tests and has been verified in a large, homogeneous study population. The uniqueness of the PER score is its simplicity because blood testing, survey of medical history, and pulmonary function testing represent the minimum diagnostic work-up necessary for esophageal surgery. In our model, cardiac risk is assessed by the RCRI, which has been validated for the prediction of operative risk in cardiac and noncardiac surgery and thus has become 1 of the most widely used risk indices.8,9,11 The PFT represents an objective test, and risk stratification is based on stringent values. The MELD score is currently considered the gold standard for the urgency of liver transplantation but has also been validated in nonhepatic surgery for mortality and morbidity.9,10 Based on these tools, the PER score can easily be calculated independent of individual assessment.

A potential bias of neoadjuvant treatment does not apply to our study population since none of our patients received preoperative chemotherapy or radiochemotherapy. Previously reported data have shown a close relationship between neoadjuvant chemoradiotherapy with increased mortality and esophageal surgery.24

Lagarde et al7 postulated the urgent need for future predictive models of EC surgery to focus not only on perioperative outcome but also on oncological survival. Until now, no score

---

**TABLE 4. Multivariate Cox Regression Analysis for Tumor Recurrence and Overall Survival**

| Variables | Tumor Recurrence | Overall Survival |
|-----------|------------------|------------------|
|           | HR    | 95% CI | \( P \) | HR    | 95% CI | \( P \) |
| Age       | 1.0   | 0.8–1.3 | 0.9   | 1.0   | 0.8–1.3 | 0.8   |
| Gender    | 0.6   | 0.4–0.9 | 0.01  | 0.8   | 0.6–1.1 | 0.1   |
| UICC stage|       |        |       |       |        |       |
| Stage I A/B vs II A/B | 1.3 | 0.8–2.1 | 0.3   | 1.5   | 1.0–2.3 | 0.04  |
| Stage I A/B vs III A/B/C | 4.0 | 2.7–5.8 | <0.001 | 3.0   | 2.1–4.2 | <0.001 |
| Stage I A/B vs IV | 9.0 | 2.7–30.2 | <0.001 | 14.1  | 5.4–36.9 | <0.001 |
| Grading   |       |        |       |       |        |       |
| G1 vs G2  | 2.2   | 0.9–5.0 | 0.07  | 2.2   | 1.1–4.5 | 0.03  |
| G1 vs G3  | 3.6   | 1.5–8.5 | 0.003 | 3.3   | 1.6–6.9 | 0.002 |
| Tumor type|       |        |       |       |        |       |
| SCC vs AC | 0.7   | 0.5–1.0 | 0.02  | 0.8   | 0.6–1.0 | 0.09  |
| Operating technique |       |        |       |       |        |       |
| TA vs TH  | 1.4   | 1.0–1.9 | 0.02  | 1.2   | 0.9–1.6 | 0.2   |
| PER       |       |        |       |       |        |       |
| PER 1 vs PER 2 | 1.1 | 0.8–1.5 | 0.04  | 1.5   | 1.1–1.9 | 0.006 |
| PER 1 vs PER 3 | 1.7 | 1.1–2.5 | 0.02  | 2.2   | 1.5–3.2 | <0.001 |

AC = adenocarcinoma, CI = confidence interval, HR = hazard ratio, PER = preoperative esophagectomy risk, SCC = squamous cell carcinoma, TA = thoracoabdominal esophagectomy, TH = transhiatal esophagectomy, UICC = Union Internationale Contre le Cancer.
has been reported being able to predict mortality, morbidity, and oncological outcome for EC. The most commonly used predictive parameters for long-term survival are tumor-specific parameters like tumor size, presence of lymph-node or distant metastases, or grade of differentiation. However, there is evidence that factors not apparently associated with the tumor, like inflammation, do correlate with the oncological outcome. The Glasgow prognostic score (GPS) has been shown to be an independent prognostic factor for survival in colorectal cancer and other kinds of cancer.\textsuperscript{25–27} Kobayashi et al.\textsuperscript{28,29} reported on the prediction value of GPS in neoadjuvant chemoradiotherapy-treated SCC patients. GPS is based on the determination of C-reactive protein and albumin as markers for inflammation. The significance of GPS has been verified by several groups\textsuperscript{30} and has been reported to be superior to blood-tumor markers like carcino-embryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) in colorectal cancer.\textsuperscript{31} In concordance to this the herein reported PER score also classified patients into 3 different groups based on preoperative risk assessment. Tumor biology may affect cardiac, pulmonary, and liver function. Another possible explanation could be that patients with less cardiac, pulmonary, or liver function are not able to react adequately or sufficiently on tumor growth and metastatic spread. Both potential explanations cannot be proven by our findings and have to be addressed in future studies.

A close relation between the presence of lymph-node metastases and the PER score and the inclusion of MI patients in our study may be considered a bias because of the close association of OS and the score. However, we were able to show the PER score remained a significant prognosticator of OS in EC patients after stratification of the presence of lymph-node and distant metastases.

Although this is the first attempt to predict postoperative outcome of esophageal surgery based on objective preoperative parameters, a short coming of our study is the lacking validation by other centers for esophageal surgery, which mandates further verification and validation of this risk score in future studies.

In conclusion, the PER score is an easy-to-determine and an objective tool. The score seems to be superior to other reported prediction models and normograms for esophageal surgery. Therefore, adoption of the PER score as a simple and convenient tool not only for the prediction of perioperative outcome in terms of mortality and morbidity but also of long-term survival in patients undergoing esophageal resection for EC, independent of underlying histology and operating technique, may be helpful to stratify patients hierarchically into different risk groups preoperatively. Thus, multicenter studies are needed for independent validation of the PER score.

REFERENCES

1. Tougeron D, Richer JP, Silvain C. Management of esophageal adenocarcinoma. J Visc Surg. 2011;148:e161–e170.
2. Morita M, Nakamoto T, Fujinaka Y, et al. In-hospital mortality after a surgical resection for esophageal cancer: analyses of the associated factors and historical changes. Ann Surg Oncol. 2011;18:1757–1765.
3. Steyerberg EW, Neville BA, Koppert LB, et al. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol. 2006;24:4277–4284.
4. Cis JM, Verhoeof C, Steyerberg EW, et al. Outcome of esophagectomy for cancer in elderly patients. Ann Thorac Surg. 2010;90:900–907.
5. Bartels H, Stein HJ, Siewert JR. Preoperative risk analysis and postoperative mortality of esophagectomy for resectable esophageal cancer. Br J Surg. 1998;85:840–844.
6. Tekkis PP, McCulloch P, Poloniecki JD, et al. Risk-adjusted prediction of operative mortality in oesophagogastric surgery with O-POSSUM. Br J Surg. 2004;91:288–295.
7. Lagarde SM, Maris AK, de Castro SM, et al. Evaluation of O-POSSUM in predicting in-hospital mortality after resection for oesophageal cancer. Br J Surg. 2007;94:1521–1526.
8. Ackland GL, Harris S, Ziahari Y, et al. Revised cardiac risk index and postoperative morbidity after elective orthopaedic surgery: a prospective cohort study. Br J Anaesth. 2010;105:744–752.
9. Northup PG, Wanamaker RC, Lee VD, et al. Model for end-stage liver disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis. Ann Surg. 2005;242:244–251.
10. Vanhuyse F, Maureira P, Mattei MF, et al. Use of the model for end-stage liver disease score for guiding clinical decision-making in the selection of patients for emergency cardiac transplantation. Eur J Cardiothorac Surg. 2013;44:134–138.
11. Quante M, Benecert C, Thelen A, et al. Experience since MELD implementation: how does the new system deliver? Int J Hepatol. 2012;2012:264015.
12. Sobin LH, Compton CC. TNM seventh edition: what’s new, what’s changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer. 2010;116:5336–5339.
13. Rice TW, Rusch VW, Ishwaran H, et al. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer. 2010;116:3763–3773.
14. Hsu PK, Wu YC, Chou TY, et al. Comparison of the 6th and 7th editions of the American Joint Committee on Cancer tumor-node-metastasis staging system in patients with resected esophageal carcinoma. Ann Thorac Surg. 2010;89:1024–1031.
15. Bartels H, Stein HJ, Siewert JR. Risk analysis in esophageal surgery. Recent Res Cancer Res. 2000;155:89–96.
16. Zafirellis KD, Fountoulakis A, Dolan K, et al. Evaluation of POSSUM in patients with oesophageal cancer undergoing resection. Br J Surg. 2002;89:1150–1155.
17. Noble F, Curtis N, Harris S, et al. Risk assessment using a novel score to predict anastomotic leak and major complications after oesophageal resection. J Gastrointest Surg. 2012;16:1083–1095.
18. Gill RA, Goodman MW, Golbus GR, et al. Aminopyrine breath test predicts surgical risk for patients with liver disease. Ann Surg. 1983;198:701–704.
19. Neary WD, Heather BP, Earnshaw JJ. The Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM). Br J Surg. 2003;90:157–165.
20. Ford MK, Beattie WS, Wijeyssundera DN. Systematic review: prediction of perioperative cardiac complications and mortality by the revised cardiac risk index. Ann Intern Med. 2010;152:26–35.
21. Hoffman N, Pruneau A, Dhillon A, et al. Revised Cardiac Risk Index (RCRI) is a useful tool for evaluation of perioperative cardiac morbidity in kidney transplant recipients. Transplantation. 2013;96:639–643.
22. Rao JY, Yeriswamy MC, Santhosh MJ, et al. A look into Lee’s score: peri-operative cardiovascular risk assessment in non-cardiac surgeries-usefulness of revised cardiac risk index. Indian Heart J. 2012;64:134–138.
23. Moitra VK, Flynn BC, Mazzeffi M, et al. Indication for surgery, the revised cardiac risk index, and 1-year mortality. Ann Vasc Surg. 2011;25:902–908.

24. Shimoji H, Karimata H, Nagahama M, et al. Induction chemotherapy or chemoradiotherapy followed by radical esophagectomy for T4 esophageal cancer: results of a prospective cohort study. World J Surg. 2013;37:2180–2188.

25. Sugimoto K, Komiyama H, Kojima Y, et al. Glasgow prognostic score as a prognostic factor in patients undergoing curative surgery for colorectal cancer. Dig Surg. 2012;29:503–509.

26. Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 2011;47:2633–2641.

27. Shafique K, Proctor MJ, McMillan DC, et al. The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients. BMC Cancer. 2013;13:292.

28. Kobayashi T, Teruya M, Kishiki T, et al. Inflammation-based prognostic score, prior to neoadjuvant chemoradiotherapy, predicts postoperative outcome in patients with esophageal squamous cell carcinoma. Surgery. 2008;144:729–735.

29. Kobayashi T, Teruya M, Kishiki T, et al. Inflammation-based prognostic score and number of lymph node metastases are independent prognostic factors in esophageal squamous cell carcinoma. Dig Surg. 2010;27:232–237.

30. Vashist YK, Loos J, Dedow J, et al. Glasgow Prognostic Score is a predictor of perioperative and long-term outcome in patients with only surgically treated esophageal cancer. Ann Surg Oncol. 2011;18:1130–1138.

31. Furukawa K, Shiba H, Haruki K, et al. The Glasgow prognostic score is valuable for colorectal cancer with both synchronous and metachronous unresectable liver metastases. Oncol Lett. 2012;4:324–328.